Science Explorer Back to mapMap
Discussion
Institution · National Research Institute

Most cited papers from National Research Institute

National Research Institute

What are the most cited papers from National Research Institute?

The most cited paper from National Research Institute is "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes" (Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al., 2021), with 2,029 citations. Next come "Dynamics of HIV viremia and antibody seroconversion in plasma donors" (1,331) and "Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes" (1,172).

Showing 50 of 60 papers. Every paper with more than 130 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine Open access 25 Jun 2021 2,029
2 Dynamics of HIV viremia and antibody seroconversion in plasma donors Eberhard W. Fiebig, David J. Wright, B. D. Rawal et al. · AIDS 27 Aug 2003 1,331
3 Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes Melanie J. Davies, Richard M. Bergenstal, Bruce W. Bode et al. · JAMA Open access 18 Aug 2015 1,172
4 Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity Thomas A. Wadden, Timothy Silleck Bailey, Liana K. Billings et al. · JAMA Open access 24 Feb 2021 1,078
5 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet 27 Jun 2021 1,057
6 Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial William Timothy Garvey, Rachel Louise Batterham, Meena Bhatta et al. · Nature Medicine Open access Oct 2022 859
7 Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) Bernard Zinman, John Gerich, John B. Buse et al. · Diabetes Care Open access 16 Mar 2009 841
8 Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Juan P. Frías, Michael Albrecht Nauck, Joanna T Van et al. · The Lancet 4 Oct 2018 819
9 Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Bernhard H. Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet Aug 2021 628
10 Anemia Is Associated with Disability and Decreased Physical Performance and Muscle Strength in the Elderly Brenda W.J.H. Penninx, Marco Pahor, Matteo Cesari et al. · Journal of the American Geriatrics Society 14 Apr 2004 570
11 Initiating Insulin Therapy in Type 2 Diabetes Philip Raskin, Elsie Allen, Priscilla A. Hollander et al. · Diabetes Care Feb 2005 561
12 Fipronil: Environmental Fate, Ecotoxicology, and Human Health Concerns Colin C. D. Tingle, Joachim A. Rother, C. F. Dewhurst et al. · Reviews of Environmental Contamination and Toxicology Book chapter 2003 515
13 Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes Murray Epstein, Gordon H. Williams, Myron H. Weinberger et al. · Clinical Journal of the American Society of Nephrology 19 Jul 2006 461
14 Cross-sectional and Prospective Relationships of Interleukin-6 and C-Reactive Protein With Physical Performance in Elderly Persons: MacArthur Studies of Successful Aging Dennis R. Taaffe, Tamara B. Harris, Luigi Ferrucci et al. · The Journals of Gerontology Series A Open access Dec 2000 443
15 Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial Juan P. Frías, Cristian Guja, Elise Hardy et al. · The Lancet Diabetes & Endocrinology 16 Sep 2016 399
16 The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients Heather M. Patton, Keyur Patel, Cynthia A. Behling et al. · Journal of Hepatology 2 Dec 2003 375
17 Chronically Depressed Mood and Cancer Risk in Older Persons Brenda W.J.H. Penninx, J. M. Guralnik, Richard J. Havlik et al. · JNCI Journal of the National Cancer Institute Open access 16 Dec 1998 351
18 Long-term therapy of chronic hepatitis B with lamivudine Daryl Lau, Farooq Khokhar, Edward C. Doo et al. · Hepatology Open access Oct 2000 350
19 The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes Juan P. Frías, Edward J. Bastyr, Louis Vignati et al. · Cell Metabolism Open access Aug 2017 325
20 Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial Ildiko Lingvay, Andrei‐Mircea Catarig, Juan P. Frías et al. · The Lancet Diabetes & Endocrinology Open access 17 Sep 2019 301
21 Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin Ralph A. DeFronzo, Andrew J. Lewin, Sanjay Dhanji Patel et al. · Diabetes Care 12 Jan 2015 296
22 Progressive versus Catastrophic Disability: A Longitudinal View of the Disablement Process Luigi Ferrucci, J. M. Guralnik, Eleanor Marie Simonsick et al. · The Journals of Gerontology Series A Open access May 1996 293
23 Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis Stephen A. Harrison, Guy W. Neff, Cynthia D. Guy et al. · Gastroenterology Open access 8 Aug 2020 271
24 10-year follow-up after interferon-α therapy for chronic hepatitis C Daryl Lau, David Erwin Kleiner, Marc G. Ghany et al. · Hepatology Open access Oct 1998 269
25 Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial Bernhard H. Ludvik, Juan P. Frías, Francisco José Tinahones et al. · The Lancet Diabetes & Endocrinology Open access 23 Feb 2018 267
26 Clarifying the Direct Relation between Total Cholesterol Levels and Death from Coronary Heart Disease in Older Persons Maria Chiara Corti, Jack M. Guralnik, Marcel E. Salive et al. · Annals of Internal Medicine 15 May 1997 266
27 Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study Edgar D. Charles, Brent A. Neuschwander‐Tetri, Juan P. Frías et al. · Obesity Open access 6 Dec 2018 254
28 Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial Michel Bazinet, Victor Pântea, Valentin Cebotarescu et al. · ˜The œLancet. Gastroenterology & hepatology Open access 29 Sep 2017 254
29 Bending of Polyelectrolyte Membrane–Platinum Composites by Electric Stimuli I. Response Characteristics to Various Waveforms Kinji Asaka, Keisuke Oguro, Yasuo Nishimura et al. · Polymer Journal Open access Apr 1995 250
30 Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology John G. McHutchison, Larry M Blatt, Maria D. de Medina et al. · Journal of Gastroenterology and Hepatology Open access Aug 2000 232
31 Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial Juan P. Frías, Naunihal S. Virdi, Praveen Raja et al. · Journal of Medical Internet Research Open access 11 Jul 2017 224
32 Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies CHRISTOF M. KAZDA, Ying Ding, Ronan P. Kelly et al. · Diabetes Care 17 Dec 2015 218
33 Dynamics of viremia in early hepatitis C virus infection Simone A. Glynn, David J. Wright, Steven H Kleinman et al. · Transfusion 31 May 2005 217
34 Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens Juan P. Frías, Michael Albrecht Nauck, Joanna T Van et al. · Diabetes Obesity and Metabolism Open access 27 Jan 2020 208
35 ASSOCIATION OF MUSCLE STRENGTH WITH MAXIMUM WALKING SPEED IN DISABLED OLDER WOMEN1 Taina Rantanen, Jack M. Guralnik, Grant Izmirlian et al. · American Journal of Physical Medicine & Rehabilitation Jul 1998 202
36 More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial Julio Rosenstock, ALICE Y.Y. CHENG, Robert A. Ritzel et al. · Diabetes Care Open access 13 Aug 2018 199
37 Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) Juan P. Frías, Enzo Bonora, Luis Nevárez Ruiz et al. · Diabetes Care Open access 4 Jan 2021 196
38 Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial Mauro Di Bari, Marco Pahor, Lonneke V. Franse et al. · American Journal of Epidemiology 2001 196
39 Effect of Spark Plasma Sintering on Densification and Mechanical Properties of Silicon Carbide Nobuyuki Tamari, Takahiro Tanaka, Koji Tanaka et al. · Journal of the Ceramic Society of Japan Open access 1995 195
40 Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy ( VERTIS MET ) Julio Rosenstock, Juan P. Frías, Dénes Páll et al. · Diabetes Obesity and Metabolism Open access 31 Aug 2017 191
41 Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study Paul Yien Kwo, Norman Gitlin, Ronald Nahass et al. · Hepatology Open access 22 Jan 2016 189
42 Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes Andrew J. Lewin, Ralph Anthony DeFronzo, Sanjay Dhanji Patel et al. · Diabetes Care 29 Jan 2015 188
43 Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial Juan P. Frías, Pernille Auerbach, HARPREET SINGH BAJAJ et al. · The Lancet Diabetes & Endocrinology 21 Jul 2021 183
44 Early Cholecystectomy Safely Decreases Hospital Stay in Patients With Mild Gallstone Pancreatitis Armen Aboulian, Tony Chan, Arezou Tory Yaghoubian et al. · Annals of Surgery 19 Mar 2010 178
45 Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Rory J. McCrimmon, Andrei‐Mircea Catarig, Juan P. Frías et al. · Diabetologia Open access 2 Jan 2020 177
46 Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial Arun Jayant Sanyal et al. · Nature Medicine Open access Feb 2023 174
47 Cognitive Impairment and Risk of Stroke in the Older Population Luigi Verruca, Jack M. Guralnik, Marcel E. Salive et al. · Journal of the American Geriatrics Society Mar 1996 170
48 Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: Correlation with clinical disease stages Hugo R. Rosen, Camette Miner, Anna W. Sasaki et al. · Hepatology Open access 2002 168
49 The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction Dave S.�B. Hoon, Fukashi Doi, A E Giuliano et al. · Cancer Aug 1995 164
50 Anemia Is Associated With Depression in Older Adults: Results From the InCHIANTI Study Graziano Onder, Brenda W.J.H. Penninx, Matteo Cesari et al. · The Journals of Gerontology Series A Open access Sep 2005 160

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.